Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index, and 1 are not checked yet.

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment

Open access
Leiphrakpam, Premila, Are, Chandrakanth · 2024 · International Journal of Molecular Sciences

Abstract

In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms25063178

Cites

143 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic of the PI3K/Akt/mTOR signaling pathway. Akt, protein kinase B; BAD, Bcl2-associated agonist of cell death; CRC, colorectal cancer; ERK, extracellular signal-regulated kinase; FOXO, forkhead box O; GSK3, glycogen synthase kinase-3, KRAS, kirsten rat sarcoma virus; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MDM2, mouse double minute 2 homolog; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; NF-κB, nuclear factor-kappa B; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF, rapidly accelerated fibrosarcoma. TSC1/2, tuberous sclerosis proteins 1/2. Created with BioRender.com (accessed on 28 December 2023).
Figure 1 Schematic of the PI3K/Akt/mTOR signaling pathway. Akt, protein kinase B; BAD, Bcl2-associated agonist of cell death; CRC, colorectal cancer; ERK, extracellular signal-regulated kinase; FOXO, forkhead box O; GSK3, glycogen synthase kinase-3, KRAS, kirsten rat sarcoma virus; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MDM2, mouse double minute 2 homolog; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; NF-κB, nuclear factor-kappa B; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF, rapidly accelerated fibrosarcoma. TSC1/2, tuberous sclerosis proteins 1/2. Created with BioRender.com (accessed on 28 December 2023).CC BY · PubMed Central
Figure 2 PI3K/Akt/mTOR targeted therapy for CRC. Created with BioRender.com (accessed on 1 March 2024).
Figure 2 PI3K/Akt/mTOR targeted therapy for CRC. Created with BioRender.com (accessed on 1 March 2024).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 144 references

Cited by

See all 193

Metadata

Authors
Leiphrakpam, P., & Are, C.
Affiliations
University of Nebraska Medical Center (US)
Corresponding author
Leiphrakpam, Premila
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-03-09
Volume
25
Issue
6
Pages
3178
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4392661434
Cited by
193
References
144
Citations by year
2026: 82 · 2025: 82 · 2024: 29
FWCI
7.89
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
colorectal cancer, PI3K/AKT/mTOR pathway, targeted therapy, drug resistance, tumor heterogeneity, metastasis, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, combination therapy
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. https://app.cochat.ai/papers/10.3390/ijms25063178
The paper
Leiphrakpam, P., & Are, C. (2024). PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063178

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.